Le Lézard
Classified in: Health
Subjects: LBR, AVO

SEIU: With a $93 Million War Chest, Dialysis Industry Poised to Spend More to Defeat This Year's Prop. 23 Than the Record $110 Million it Spent in 2018


SACRAMENTO, Calif., Oct. 1, 2020 /PRNewswire/ -- With five weeks to go until the November election, dialysis corporations are poised to spend even more to defeat this year's Proposition 23 than the record $110 million they shelled out two years ago against another measure to reform the dialysis industry, Proposition 8.

At this stage of the campaign, the industry already has spent more money and amassed a war chest that is bigger than two years ago. Once again the industry has shown a willingness to spend massive amounts to protect its outsized profits in California, a total of nearly $600 million in earnings in the most recent reporting year, 2018.

"There they go again," said Ida Panell, a dialysis patient at Satellite Healthcare in San Francisco. "All Prop. 23 does is ask the industry to direct more of its profits to improving the clinics where we get our treatment, but the sky's the limit when it comes to their spending to protect their huge profits, millions for executive salaries and expensive perks. Their priority appears to be money. Our priority is staying healthy and alive."

This year, the industry has already raised $93 million and spent $85.7 million, compared with $65.3 million and $47 million respectively two years ago. The new spending includes:

Dialysis is a dangerous procedure for patients with end stage renal disease whose kidneys either aren't functioning or are not functioning properly. It involves removing a patient's blood, cleaning it, and then returning it to the body. It must be done 3 times a week for 3 to 4 hours, and must be done for a patient's entire life or until they receive a kidney transplant. It puts patients at risk of serious complications, including heart attacks, large fluctuations in blood pressure, and loss of consciousness.

Proposition 23 does four things to protect the health and safety of dialysis patients:

  1. Requires a physician or nurse practitioner to be in the clinic any time patients are being treated to oversee care, make sure safety and sanitation protocols are followed, and be there for the inevitable complications that arise.
  2. Requires clinics to report accurate data on infections to the state and federal governments so patients and their families can access the information and make informed decisions on which clinics to utilize.
  3. Like all other life-saving health care facilities, stops clinics from being closed or reducing services unless approved by the state. This is designed to protect patients in rural communities or those who would have to travel long distances if their clinic closed because the dialysis industry the location is not making enough money.
  4. Prohibits clinics from discriminating against patients because of the type of insurance they have.

Although the "Yes on 23" side is being heavily outspent by the dialysis industry, a recent poll by Survey USA shows the measure with more than a 2-1 lead, with 49 percent of voters in support and 23 percent against.

SEIU-United Healthcare Workers West (SEIU-UHW) is one of the largest unions of hospital workers in the United States, with 97,000 members. Learn more at www.seiu-uhw.org.

SOURCE SEIU-United Healthcare Workers West


These press releases may also interest you

at 20:31
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

at 19:35
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

at 18:36
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...

at 17:55
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...

at 17:53
The following statement is being issued by Rice Harbut Elliott LLP regarding the Ruckman v. Biotrade Canada Ltd. et al. lawsuit: All persons in Canada who purchased or ingested U-Dream on or after August 18, 2014 (the "Class" or "Class Members")...



News published on and distributed by: